{"id":3859,"date":"2018-10-03T12:05:13","date_gmt":"2018-10-03T10:05:13","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/10\/LNC_PR_OBEMINALE2_Venglish_102018.pdf"},"modified":"2018-10-03T12:08:47","modified_gmt":"2018-10-03T10:08:47","slug":"lnc_pr_obeminale2_venglish_102018-2","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/lnc-therapeutics-launches-a-new-clinical-trial-obeminale-2-and-treats-its-first-patient\/lnc_pr_obeminale2_venglish_102018-2\/","title":{"rendered":"LNC_PR_OBEMINALE2_Venglish_102018"},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-3859","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>LNC_PR_OBEMINALE2_Venglish_102018 | Seventure<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/10\/LNC_PR_OBEMINALE2_Venglish_102018.pdf\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/10\/LNC_PR_OBEMINALE2_Venglish_102018.pdf\",\"url\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/10\/LNC_PR_OBEMINALE2_Venglish_102018.pdf\",\"name\":\"LNC_PR_OBEMINALE2_Venglish_102018 | Seventure\",\"isPartOf\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\"},\"datePublished\":\"2018-10-03T10:05:13+00:00\",\"dateModified\":\"2018-10-03T10:08:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/10\/LNC_PR_OBEMINALE2_Venglish_102018.pdf#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/10\/LNC_PR_OBEMINALE2_Venglish_102018.pdf\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/10\/LNC_PR_OBEMINALE2_Venglish_102018.pdf#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.seventure.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LNC Therapeutics launches a new clinical trial, OBEMINALE 2, and treats its first patient\",\"item\":\"https:\/\/www.seventure.fr\/en\/lnc-therapeutics-launches-a-new-clinical-trial-obeminale-2-and-treats-its-first-patient\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"LNC_PR_OBEMINALE2_Venglish_102018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\",\"url\":\"https:\/\/www.seventure.fr\/en\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.seventure.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LNC_PR_OBEMINALE2_Venglish_102018 | Seventure","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/10\/LNC_PR_OBEMINALE2_Venglish_102018.pdf","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/10\/LNC_PR_OBEMINALE2_Venglish_102018.pdf","url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/10\/LNC_PR_OBEMINALE2_Venglish_102018.pdf","name":"LNC_PR_OBEMINALE2_Venglish_102018 | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2018-10-03T10:05:13+00:00","dateModified":"2018-10-03T10:08:47+00:00","breadcrumb":{"@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/10\/LNC_PR_OBEMINALE2_Venglish_102018.pdf#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/10\/LNC_PR_OBEMINALE2_Venglish_102018.pdf"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/10\/LNC_PR_OBEMINALE2_Venglish_102018.pdf#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"LNC Therapeutics launches a new clinical trial, OBEMINALE 2, and treats its first patient","item":"https:\/\/www.seventure.fr\/en\/lnc-therapeutics-launches-a-new-clinical-trial-obeminale-2-and-treats-its-first-patient\/"},{"@type":"ListItem","position":3,"name":"LNC_PR_OBEMINALE2_Venglish_102018"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"description":{"rendered":"<p class=\"attachment\"><a href='https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/10\/LNC_PR_OBEMINALE2_Venglish_102018.pdf'>LNC_PR_OBEMINALE2_Venglish_102018<\/a><\/p>\n"},"caption":{"rendered":"<p>LNC_PR_OBEMINALE2_Venglish_102018<\/p>\n"},"alt_text":"","media_type":"file","mime_type":"application\/pdf","media_details":{},"post":3863,"source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/10\/LNC_PR_OBEMINALE2_Venglish_102018.pdf","_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media\/3859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/attachment"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=3859"}]}}